Literature DB >> 8331205

Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery.

J C Fleishaker1, T A Sisson, J J Sramek, J Conrad, A E Veroff, N R Cutler.   

Abstract

The memory effects of adinazolam were assessed using the computerized neuropsychological test battery (CNTB). In a single-blind crossover study, 12 volunteers received 2 x 20 mg adinazolam mesylate immediate-release (CT) tablets, 2 x 30 mg sustained-release (SR) tablets, and placebo. Plasma adinazolam and N-desmethyladinozolam (NDMAD) were determined by high-pressure liquid chromatography. Choice reaction time and word-list-learning/delayed-recall CNTB modules were administered at 0, 1, 3 and 6 hours after dosing. Adinazolam and NDMAD maximum peak plasma concentration were lower after SR tablets. Immediate-release tablets significantly prolonged reaction time compared with placebo and SR tablets; reaction time after SR tablets did not differ from placebo. Differences between SR and CT tablets in memory were significant only at 1 hour, but memory scores tended to be higher after SR tablet administration than after the CT tablet. At all times, memory scores were significantly lower than placebo for active treatments. Results suggest that memory is more impaired at lower NDMAD concentrations than is psychomotor function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8331205     DOI: 10.1002/j.1552-4604.1993.tb04689.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Authors:  Viera Lukacova; Walter S Woltosz; Michael B Bolger
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

2.  Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects.

Authors:  J C Fleishaker; P D Garzone; J H Chambers; K Sirocco; H Weingartner
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.